U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT07569757) titled 'Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma' on April 29.
Brief Summary: This study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma. The estimated total sample size is 260 cases, who will be randomly assigned in a 1:1 ratio to the test group and the control group. The primary objective of the study is to demonstrate the efficacy of TQB2934 for injection compared to the investigator-selected regimen in subjects with relapsed or refractory multiple myeloma (RRMM) by evaluating progression-free survival (PFS).
Study Start Date:...